Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2009 - 2026)

Regeneron Pharmaceuticals' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $123.2 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 2.92% year-over-year to $123.2 million in Q1 2026; TTM through Mar 2026 was $540.0 million, a 8.94% increase from a year earlier, with the FY2025 full-year figure at $543.7 million, up 12.59% from the prior year.
• Depreciation & Amortization (CF) eased to $123.2 million in Q1 2026 per REGN's latest filing, from $145.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $145.0 million in Q4 2025 and bottomed at $74.3 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $114.1 million (2024), against an average of $112.5 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 38.58% in 2023 and retreated 2.92% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $100.1 million in 2022, then rose by 12.89% to $113.0 million in 2023, then increased by 11.86% to $126.4 million in 2024, then increased by 14.72% to $145.0 million in 2025, then fell by 15.03% to $123.2 million in 2026.
• Per Business Quant, the three latest REGN Depreciation & Amortization (CF) figures stand at $123.2 million (Q1 2026), $145.0 million (Q4 2025), and $136.7 million (Q3 2025).